Related Experiment Video

Updated: Jan 6, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.1K

Novel treatment strategies for myeloproliferative neoplasms

Prithviraj Bose1, Lucia Masarova1, Srdan Verstovsek1

  • 1Department of Leukemia, MD Anderson Cancer Center.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 11, 2019
PubMed

Insights

Ropeinterferon alfa is a new treatment for polycythemia vera, while new Janus kinase (JAK) inhibitors and other targeted therapies are in development for myelofibrosis and other rare blood cancers.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Ruxolitinib remains the sole approved Janus kinase (JAK) inhibitor for Philadelphia chromosome-negative myeloproliferative neoplasms.
  • Recent European approval of ropeginterferon alfa for polycythemia vera signifies progress in treatment options.
  • Emerging therapies target myelofibrosis, chronic neutrophilic leukemia, FGFR1-rearranged neoplasms, and systemic mastocytosis.

Purpose of the Study:

  • To review recent advancements in drug development for Philadelphia chromosome-negative myeloproliferative neoplasms.
  • To highlight novel therapeutic agents and their potential applications in specific hematologic malignancies.
  • To underscore the evolving landscape of treatment strategies, including new targets and combination therapies.

Main Methods:

  • Review of recent clinical trial data and regulatory approvals for myeloproliferative neoplasms and related disorders.
  • Analysis of therapeutic agents targeting JAK signaling pathways, fibroblast growth factor receptors (FGFR), and KIT mutations.
  • Examination of emerging treatment paradigms focusing on symptom management, anemia improvement, and specific molecular drivers.

Main Results:

  • Ropeinterferon alfa approved in Europe for polycythemia vera.
  • Several novel JAK inhibitors (fedratinib, pacritinib, momelotinib) show promise in myelofibrosis trials.
  • Pemigatinib and avapritinib demonstrate significant efficacy in FGFR1-rearranged neoplasms and advanced systemic mastocytosis, respectively.

Conclusions:

  • The therapeutic landscape for Philadelphia chromosome-negative myeloproliferative neoplasms is rapidly expanding with new drug approvals and ongoing clinical development.
  • Targeted therapies are showing remarkable efficacy in specific hematologic malignancies, addressing unmet needs beyond traditional JAK inhibition.
  • Future research directions include combination therapies and agents aimed at improving anemia in myelofibrosis patients.
Keywords:
JAK inhibitorsKIT inhibitorsMyeloproliferative neoplasmsSystemic mastocytosis

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.0K
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
798
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K